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Abstract
Background: The multi-arm multi-stage framework uses intermediate outcomes to assess lack-of-benefit of research
arms at interim stages in randomised trials with time-to-event outcomes. However, the design lacks formal methods to
evaluate early evidence of overwhelming efficacy on the definitive outcome measure. We explore the operating charac-
teristics of this extension to the multi-arm multi-stage design and how to control the pairwise and familywise type I
error rate. Using real examples and the updated nstage program, we demonstrate how such a design can be developed
in practice.
Methods: We used the Dunnett approach for assessing treatment arms when conducting comprehensive simulation
studies to evaluate the familywise error rate, with and without interim efficacy looks on the definitive outcome measure,
at the same time as the planned lack-of-benefit interim analyses on the intermediate outcome measure. We studied the
effect of the timing of interim analyses, allocation ratio, lack-of-benefit boundaries, efficacy rule, number of stages and
research arms on the operating characteristics of the design when efficacy stopping boundaries are incorporated.
Methods for controlling the familywise error rate with efficacy looks were also addressed.
Results: Incorporating Haybittle–Peto stopping boundaries on the definitive outcome at the interim analyses will not
inflate the familywise error rate in a multi-arm design with two stages. However, this rule is conservative; in general,
more liberal stopping boundaries can be used with minimal impact on the familywise error rate. Efficacy bounds in trials
with three or more stages using an intermediate outcome may inflate the familywise error rate, but we show how to
maintain strong control.
Conclusion: The multi-arm multi-stage design allows stopping for both lack-of-benefit on the intermediate outcome
and efficacy on the definitive outcome at the interim stages. We provide guidelines on how to control the familywise
error rate when efficacy boundaries are implemented in practice.
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Introduction
The multi-arm multi-stage (MAMS) adaptive clinical
trial design developed by Royston et al.1,2 has many
practical advantages when evaluating treatments, such
as increased efficiencies in time and patients required,
and a greater probability of success than a traditional
parallel-group, single-stage design.3 Interim stages are
used to identify early evidence of lack-of-benefit of
each research arm over the control arm. The MAMS
framework utilises an intermediate (I) outcome mea-
sure for interim assessment, which is correlated with
the definitive (D) primary outcome measure but may be
observed earlier. The I-outcome may be composite,
including the D-outcome. In time-to-event settings, the
events required to trigger the interim analyses are
accrued more quickly on the I-outcome, so decisions to
drop arms for lack-of-benefit can be made earlier if
I 6¼ D than if the primary outcome is used throughout
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(I=D). While other MAMS designs have been pro-
posed, the framework considered here is unique in its
application to time-to-event outcomes. The design has
been implemented successfully in several randomised
trials, some of which have been described in a recent
article in Clinical Trials.4
Efficacy stopping boundaries can be implemented as
a means of assessing interim data as they accumulate to
identify treatment arms indicating overwhelming efficacy
over the course of the trial. Data monitoring committees
may recommend terminating a trial before its planned
end in order to report the results, or be submitted for
regulatory approval, earlier than planned. Permitting
early stopping for efficacy would increase the efficiency
of the MAMS design further, by minimising patients
being exposed to inferior treatment regimens and
decreasing the time for effective treatments to reach
patients. Popular stopping boundaries are the Haybittle–
Peto rule,5 the O’Brien–Fleming rule6 and other
approaches utilising an alpha-spending function.7,8
Multiple testing in MAMS trials may increase the
risk of a type I error,9 also known as the pairwise error
rate (PWER) in two-arm designs. In a multi-arm set-
ting, it is generally referred to as the familywise error
rate (FWER): the probability of at least one ineffective
research arm being recommended at an interim stage
or at the end of the trial. Whether or not the FWER
should be controlled in a MAMS trial should be
decided on a case-by-case basis. However, it may be
important that its value is calculated, even in trials that
do not require strong control of the FWER.10
As far as we are aware, no alternative MAMS trial
design formally assesses lack-of-benefit on an inter-
mediate outcome and efficacy on the definitive out-
come simultaneously at interim analyses for time-to-
event data. For this reason, this extension to the exist-
ing framework of Royston and colleagues,11,12 and the
development of the associated nstage software, will
provide the necessary evidence required by regulatory
agencies to allow interim efficacy guidelines to be
incorporated into MAMS designs and allow trials to
measure and control the impact on the operating char-
acteristics of the design.
This article explores this design extension via a simu-
lation study, to quantify the extent to which the error
rates are affected by formal interim efficacy looks
according to different design parameters. We also illus-
trate how the FWER can be controlled in practice by
modifying the design specification, using real MAMS
trials as examples.
MAMS in practice: the STAMPEDE trial
Table 1 illustrates how the MAMS proposal has been
applied to a clinical trial evaluating systemic therapies
in prostate cancer.13 STAMPEDE was initially
designed as a six-arm, four-stage trial, using the com-
posite intermediate outcome measure of failure-free
survival (FFS), for assessing lack-of-benefit at interim
stages, and a definitive outcome of overall survival
(OS) at the final analysis for efficacy. Table 1 shows
the design specification for the original treatment com-
parisons at each stage: the outcome measure, target
hazard ratio (HR) under the alternative hypothesis for
the research arms (HR1), power (vj), significance level
(aj), critical HR to drop arms for lack-of-benefit and
control arm events required to trigger each analysis. All
p-values are one sided.
Methods
The MAMS design
For a K-arm, J-stage trial, one-sided significance levels
are specified for stages 1 to J to compare each of the
research arms against the control arm on the intermedi-
ate outcome at interim analyses and definitive outcome
at the final analysis. No formal comparisons are made
between the research arms. The design targets high
pairwise power at interim stages (e.g. 95%) to increase
the probability of continuing with promising research
arms.2 For the chosen power, the stagewise significance
levels form a boundary for lack-of-benefit, since rejec-
tion of the null hypothesis at an interim analysis indi-
cates that the arm continues recruitment to the
subsequent stage.
The timing of interim analyses is driven by the num-
ber of intermediate outcome events observed in the
control arm for trials with time-to-event outcomes and
is determined by how liberal or conservative the
Table 1. Design specification for the six-arm four-stage STAMPEDE trial. HR1 is the target hazard ratio; vj and aj are the power and
significance level, respectively, for stage j.
Stage (j) Type Outcome measure HR1 vj (%) aj Critical HR Control arm events
1 Activity FFS 0.75 95 0.50 1.0 113
2 Activity FFS 0.75 95 0.25 0.92 216
3 Activity FFS 0.75 95 0.10 0.89 334
4 Efficacy OS 0.75 90 0.025 – 403
HR: hazard ratio; FFS: failure-free survival; OS: overall survival.
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significance levels are. Large p-values indicate early
interim analyses, requiring only a small number of
events. More conservative boundaries, with smaller p-
values, trigger relatively later interim analyses when
more events have been accrued. At each interim analy-
sis, research arms demonstrating lack-of-benefit on the
intermediate outcome may be dropped from the subse-
quent stages, optimising resources in the ongoing trial.
By allowing the specification of an efficacy boundary,
recruitment can also be terminated early to the research
arms demonstrating overwhelming evidence of efficacy
on the definitive outcome at an interim analysis.
Detailed guidelines for designing a MAMS trial are
provided in Supplemental Appendix A.
In the MAMS design, correlation is induced between
the estimated treatment effects of pairwise comparisons
in two ways: first due to the shared control arm and sec-
ond due to the shared or correlated outcome measures
across stages. In the case of STAMPEDE, the inter-
mediate and definitive outcome measures were strongly
correlated due to FFS being a composite measure of OS
(see Supplemental Appendix C), but the source of the
correlation may differ for alternative outcome measures.
Type I error rate
In the MAMS setting, type I errors can only be made
on decisions based on the definitive outcome. The
PWER for comparison k is defined as the probability
of a type I error made on comparison k, while the
FWER is the probability of a type I error made on any
pairwise comparison.
For a design where I =D, assuming that lack-of-
benefit boundaries are binding, the PWER is condi-
tional on the probability of treatment arms not being
dropped for lack-of-benefit at previous stages. When
efficacy boundaries are implemented, the PWER can
be calculated as follows
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where (z1k , . . . , zJk) is a realisation of the (Z1k , . . . , ZJk)
test statistics comparing the experimental arm
k= 1, . . . ,K against the control arm at stage
j= 1, . . . , J , with each Zjk following a standard normal
distribution; l1, . . . , lJ are the upper boundaries for
lack-of-benefit and b1, . . . , bJ are the lower bounds for
efficacy in the time-to-event setting and S2, . . . ,SJ are
the correlation matrices under the null hypothesis for
the kth comparison, Hk0 (see Supplemental Appendix C
for an example).
To calculate the FWER, the union of all events lead-
ing to a type I error is considered. The probability also
depends on whether the trial continues with the remain-
ing arms or is terminated when a research arm crosses
the efficacy boundary. In the former case, when I=D,
the FWER is calculated by considering all permutations
of type I errors possible across the pairwise comparisons
under the assumption that all research arms are ineffec-
tive on D (the global null).14 For the latter scenario, an
analytical solution has been derived.15,16 We compared
these two approaches empirically by simulation.
In cases where an intermediate outcome measure is
used for assessing lack-of-benefit at interim (I 6¼ D), the
maximum PWER is considered. This measure assumes
that each research arm appears sufficiently effective on
I to pass all lack-of-benefit assessments under the global
null on D. Thus, the lack-of-benefit stopping bound-
aries are considered non-binding; hence, where no effi-
cacy looks are permitted, it has been shown that the
maximum PWER is equal to the final-stage significance
level of the design (aJ ).
17 When efficacy bounds are
implemented on the definitive outcome, it is equal to
the probability of a type I error made at an interim or
the final stage. The maximum FWER for a design with
efficacy bounds can correspondingly be evaluated by
considering all permutations of type I errors across the
pairwise comparisons, assuming non-binding lack-of-
benefit bounds. Analytical solutions can be obtained as
above, by calculating the correlation structure
P
and
replacing the lack-of-benefit bounds with infinity.
Power
The power of a clinical trial is the probability an effec-
tive treatment is identified by the final analysis. In the
MAMS setting, assuming binding boundaries, the
power is conditional on the treatment arm passing all
interim stages prior to rejection of the null hypothesis,
without being dropped for lack-of-benefit. Three differ-
ent definitions of power can be calculated in multi-arm
trials: per-pair, any-pair and all-pair powers.18 Per-pair
power is the probability of detecting a treatment effect
in a particular arm. Any-pair power is the probability
of detecting at least one true treatment effect among
several arms and all-pair power is the probability of
detecting every true treatment effect from all pairwise
comparisons. The measures are calculated under the
global alternative hypothesis: the assumption that all
research arms are effective. The three measures of
power will be identical in a two-arm trial,19 but when
considering a multi-arm design the power measure of
interest may depend on the objective of the trial. When
efficacy bounds are implemented, per-pair power can
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be evaluated using a generalised form of equation (1)
under the alternative hypothesis HA (see Supplemental
Appendix B).
Simulation study
Treatment arm–level data were simulated for 3 mil-
lion trials. The type I error measure of interest was
the PWER for two-arm scenarios and the FWER for
multi-arm settings. Multi-arm scenarios considered
the three measures of powers previously defined in
section ‘Power’. Operating characteristics were evalu-
ated empirically from the simulation results, though
were compared against analytical solutions for the
two-arm scenarios.
We explored the impact of implementing efficacy
stopping rules on the type I error and power under dif-
ferent plausible design specifications which may be
implemented in a MAMS trial, as described below. A
separate stopping rule20 was assumed for all the results
presented, with operating characteristics calculated
assuming that the trial continues with the remaining
research arms if any one arm is dropped early for effi-
cacy. However, the impact of terminating the trial after
this occurrence was also investigated, since in some
cases it may be unethical to continue the trial. This
approach to stopping early for efficacy has been termed
a simultaneous stopping rule.
Simulations under an I 6¼ D design assume non-
binding lack-of-benefit boundaries, but both binding
and non-binding stopping rules were considered when
I =D to explore the sensitivity of the results to the
assumption of binding boundaries.
Definition of simulation parameters
Efficacy stopping rule. The form of the efficacy stopping
rule will determine how stringent the boundaries
aE1, . . . ,aEJ are. A three-stage design was used to
examine the impact of varying the first- and second-
stage efficacy bounds, where the third bound was fixed
at the final-stage significance level to ensure a meaning-
ful conclusion to the trial (aEJ =aJ = 0:025).
Assuming survival outcomes, only beneficial treat-
ment effects were considered (i.e. HR \ 1) so the lack-
of-benefit thresholds serve as an upper boundary and
the efficacy thresholds as a lower boundary. The direc-
tion of these may differ for alternative outcomes.
The Haybittle–Peto guideline5 uses the same thresh-
old at stages 1 to J  1. Under this guideline, the simu-
lations required a one-sided p-value of 0.0005 to declare
overwhelming efficacy at interim for a treatment com-
parison on the D-outcome. The O’Brien–Fleming
guideline6 adjusts the threshold at each stage required
to declare efficacy in order to control the overall prob-
ability of a type I error at a prespecified level. It is based
on the information time t: the proportion of events
observed by interim analysis j out of the total expected
by the final-stage analysis. An alpha-spending function
to approximate the O’Brien–Fleming boundary was
provided by DeMets and Lan.21 We also explored the
impact of ‘custom’ efficacy boundaries, which allow
greater flexibility in how liberal or conservative each
interim assessment should be in order to stop early for
efficacy.
The Haybittle–Peto guideline was used as a default
rule when investigating other design parameters, since
it is unaffected by the timing of the stages.
Other design parameters. Table 2 shows the range of val-
ues used in the simulation study, for the parameters
known to have an influence on the operating character-
istics of the MAMS design. The times at which the
interim analyses are to be conducted are dictated by
the stagewise significance levels for assessing lack-of-
benefit. A large aj is recommended in the first stage to
trigger an early interim analysis for lack-of-benefit
while retaining high power, with the function aj= 0:5
j
(j= 1, . . . , J ) suggested by Royston et al.2
We used one-sided lack-of-benefit boundaries of
a=(0:1, 0:025) for the two-stage, a=(0:25, 0:1, 0:025)
for the three-stage and a=(0:5, 0:25, 0:1, 0:025) for the
four-stage simulations. The default value for the final-
stage significance level was fixed at aJ = 0:025 for all
simulations, to reflect the conventional test for assessing
efficacy, for example, in the STAMPEDE trial.13 We
carried out simulations under both I=D and I 6¼ D
designs, where I is FFS with a HR of 1 under the null
and 0.70 under the alternative and D is OS with a HR
of 1 under the null and 0.75 under the alternative. The
strength of correlation between the treatment effects on
I and D does not strongly influence the maximum error
rates, since non-binding boundaries are assumed when
an intermediate outcome is used to assess lack-of-bene-
fit, and type I errors can only be made on the definitive
outcome.
Strong control of the FWER
Controlling the FWER in the strong sense limits its
value under any underlying treatment effect of the I- or
Table 2. Simulation parameter values.
Design parameter Simulation inputs
Number of comparisons 1, 2, 3, 4, 5
Number of stages 2, 3, 4
Allocation ratio 0.5, 0.6, 0.7, 0.8, 0.9, 1
Final-stage significance level 0.01, 0.025, 0.05
a1 0.1, 0.2, 0.3, 0.4, 0.5
Outcome measures I=D, I 6¼ D
Number of simulations 3,000,000
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D-outcomes. The maximum FWER is calculated by
assuming non-binding lack-of-benefit boundaries, such
that all research arms pass all interim stages. The actual
FWER of the trial must be less than or equal to this
maximum and so it is controlled.
A program was written using linear interpolation to
determine the final-stage significance level (aJ ) required
to strongly control the FWER at the prespecified level.
This was run both with and without efficacy bound-
aries and the designs were compared to their original
specifications. The incremental adjustment to aJ and
the additional control arm events required with the
implementation of efficacy bounds to the design was
measured.
We applied this method to two MAMS trials utilis-
ing an intermediate outcome measure (i.e. I 6¼ D):
ICON522 and STAMPEDE.3,13 Both trials aimed to
control the PWER instead of the FWER, since the
research questions in each pairwise comparison were
assumed distinct at the time of the design. However, we
show how strong control of the FWER at 2.5% (one-
sided) could have been achieved.
Results
Simulation results
Two-arm designs. Our simulations indicate that in a two-
arm two-stage design the inclusion of the Haybittle–Peto
efficacy rule at the interim stage has a minimal impact
on the PWER under any configuration of the timing of
interim analysis, the value of the final-stage significance
level and the design allocation ratio. See Supplemental
Appendix E for further details of these results. The
extent of inflation of the FWER is determined by the
choice of efficacy stopping boundary and whether an
intermediate outcome is used (see Table 3). While non-
binding lack-of-benefit boundaries increase the absolute
FWER, the relative inflation is no larger than that under
binding boundaries so the assumed approach does not
affect the interpretation of the results presented.
Implementing the Haybittle–Peto rule in a three-
stage design (aEj= 0:0005 at each interim stage) inflates
the FWER by less than 1% when outcomes I and D are
equal and the maximum FWER by 2% when different,
so it can be implemented with minimal penalty on the
Table 3. Impact of the choice of efficacy boundary (EB) aE1, . . . ,aE3 on the type I error rate (all SEs\ 0.0002; lack-of-benefit
boundaries = 0.25, 0.1, 0.025; allocation ratio = 1).
Type I error rate Power
Rule aE1 aE2 aE3 No EB With EB Inflation Percentage No EB With EB
I=D, binding Peto 0.0005 0.0005 0.0250 0.0224 0.0225 0.0001 0 0.8771 0.8771
Custom 0.0005 0.0010 0.0250 0.0224 0.0225 0.0001 0 0.8771 0.8771
Custom 0.0005 0.0020 0.0250 0.0224 0.0226 0.0002 1 0.8771 0.8771
Custom 0.0005 0.0050 0.0250 0.0224 0.0229 0.0005 2 0.8771 0.8771
Custom 0.0005 0.0100 0.0250 0.0224 0.0242 0.0018 8 0.8771 0.8771
Custom 0.0010 0.0010 0.0250 0.0224 0.0227 0.0003 1 0.8771 0.8771
Custom 0.0010 0.0020 0.0250 0.0224 0.0227 0.0003 1 0.8771 0.8771
Custom 0.0010 0.0050 0.0250 0.0224 0.0230 0.0006 3 0.8771 0.8771
Custom 0.0010 0.0100 0.0250 0.0224 0.0243 0.0019 8 0.8771 0.8771
O’Brien 0.0022 0.0139 0.0250 0.0224 0.0261 0.0037 17 0.8771 0.8771
I=D, non-binding Peto 0.0005 0.0005 0.0250 0.0250 0.0250 0.0000 0 0.8999 0.8999
Custom 0.0005 0.0010 0.0250 0.0250 0.0250 0.0000 0 0.8999 0.8999
Custom 0.0005 0.0020 0.0250 0.0250 0.0251 0.0001 0 0.8999 0.8999
Custom 0.0005 0.0050 0.0250 0.0250 0.0254 0.0004 2 0.8999 0.8999
Custom 0.0005 0.0100 0.0250 0.0250 0.0267 0.0017 7 0.8999 0.8999
Custom 0.0010 0.0010 0.0250 0.0250 0.0252 0.0002 1 0.8999 0.8999
Custom 0.0010 0.0020 0.0250 0.0250 0.0255 0.0002 1 0.8999 0.8999
Custom 0.0010 0.0050 0.0250 0.0250 0.0268 0.0005 2 0.8999 0.8999
Custom 0.0010 0.0100 0.0250 0.0250 0.0287 0.0018 7 0.8999 0.8999
O’Brien 0.0022 0.0139 0.0250 0.0250 0.0282 0.0037 13 0.8999 0.8999
I 6¼ D, non-binding Peto 0.0005 0.0005 0.0250 0.0250 0.0255 0.0005 2 0.9002 0.9002
Custom 0.0005 0.0010 0.0250 0.0250 0.0258 0.0008 3 0.9002 0.9002
Custom 0.0005 0.0020 0.0250 0.0250 0.0264 0.0014 6 0.9002 0.9002
Custom 0.0005 0.0050 0.0250 0.0250 0.0285 0.0035 14 0.9002 0.9002
Custom 0.0005 0.0100 0.0250 0.0250 0.0323 0.0073 29 0.9002 0.9002
Custom 0.0010 0.0010 0.0250 0.0250 0.0261 0.0011 4 0.9002 0.9002
Custom 0.0010 0.0020 0.0250 0.0250 0.0267 0.0017 7 0.9002 0.9002
Custom 0.0010 0.0050 0.0250 0.0250 0.0287 0.0037 15 0.9002 0.9002
Custom 0.0010 0.0100 0.0250 0.0250 0.0324 0.0074 30 0.9002 0.9002
O’Brien \0.0001 0.0001 0.0250 0.0250 0.0250 0.0000 0 0.9002 0.9002
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type I error in both settings. Less conservative rules
may result in larger inflation of the error rates, illu-
strated in Table 3.
For a design where I = D and aE1= 0:0005, custom
second-stage efficacy bounds of aE2= 0:001 or 0:002
have no impact on the type I error rate. Increasing aE2
to 0.005 and 0.01 shows the FWER may be inflated by
2% and 8%, respectively, suggesting that a custom
second-stage boundary can increase the Haybittle–Peto
bound 10-fold with minimal impact on the FWER.
Increasing aE1 to 0.001 only inflates the FWER with
liberal second-stage efficacy boundaries (aE2.0:005),
suggesting that the efficacy bound at the first interim
analysis can be less conservative than the Haybittle–
Peto bound. When I 6¼ D, the inflation is much larger
than that when I = D where custom boundaries are
used with a liberal second-stage p-value, with the
FWER inflated by up to 15% when aE2= 0:005 and
by almost a third when aE2= 0:01 (aE1ł 0:001).
An O’Brien–Fleming type rule inflates the FWER
the most by 17% when I = D, due to the liberal p-val-
ues required at the first two stages to declare efficacy
(e.g. aE2= 0:0139). When I 6¼ D, this is the only rule
where the inflation of the FWER is smaller than that
when I = D, due to the I-outcome measure allowing
the interim analyses to occur much earlier with a
smaller number of D-events. Thus, the spending func-
tion requires very small p-values (\0.0001) at the early
interim stages to declare efficacy, and as such no infla-
tion of the maximum FWER is incurred under this trial
design when I 6¼ D.
MAMS designs. Table 4 shows the impact of increasing
the number of pairwise comparisons and stages when
I = D and I 6¼ D assuming binding and non-binding
lack-of-benefit boundaries, respectively. Increasing the
number of pairwise comparisons in a two-stage design
incurs no inflation of the FWER when I = D and the
relative inflation remains below 2% when I 6¼ D.
The relative inflation increases with the number of
stages in the trial, as the number of opportunities to
drop arms early for efficacy increases. However, the
inflation when I = D is arguably negligible at less than
2%, and the maximum FWER inflation remains below
5% when I 6¼ D for a trial with up to four stages.
Extending the design to MAMS settings does not
materially change the results observed from the two-
arm two-stage simulations. While the absolute FWER
naturally increases, there is no impact on the relative
effect of incorporating efficacy looks with more
research arms, and the relative inflation when increas-
ing stages remains constant with any number of arms.
In accordance with Table 3, an O’Brien–Fleming
type rule implemented in a MAMS design inflates the
FWER by up to 17% when I = D, but no inflation of
the maximum FWER is observed when I 6¼ D (see
Supplemental Appendix E).
The three power measures are almost unaffected by
the implementation of efficacy boundaries for all possi-
ble design configurations. The induced between-arm
correlation due to the common control arm is found to
increase all-pair power, compared to a design with inde-
pendent treatment arms, and (negligibly) decrease any-
pair power.
When adopting a simultaneous stopping rule, the
FWER is unaffected by whether or not the trial termi-
nates early compared to a separate stopping rule. Since
the FWER measures the probability of at least one type
I error under the global null, type I errors made after an
arm is dropped for efficacy do not increase the FWER.
Simulations found that the PWER decreases marginally
(e.g. by 0.001 for a four-stage design with four arms).
Example: implementing efficacy boundaries in
MAMS trials
The operating characteristics for the example MAMS
trials STAMPEDE and ICON5 are shown in Table 5
for the original design specifications and with each of
the three efficacy stopping rules. Both trials observe
some inflation of the type I error when efficacy bounds
are hypothetically incorporated, due to the use of an
intermediate outcome, reflecting the theoretical results
observed in the simulation study. How to control the
FWER in these trials for such stopping rules is also
demonstrated.
The two-stage ICON5 trial, when retrospectively
designed with the Haybittle–Peto stopping rule, would
require the final-stage significance level aJ to be
reduced minimally by 0.0004, with only five (\1%)
additional control arm events to be observed, in order
to maintain the same level of FWER control as only
assessing for lack-of-benefit. The O’Brien–Fleming type
rule can be implemented without any further adjust-
ment to aJ , but the probability of dropping arms early
for efficacy is very low at interim (\0.0001).
Controlling the FWER with a ‘custom’ efficacy bound-
ary of aE = 0:001 at the interim analysis would require
2% more control arm events, and the greatest reduc-
tion in aJ of the three rules to 0.0064, but in general
settings the degree of adjustment will depend on the
specific custom boundary used. Note that recruitment
to ICON5 was discontinued at the interim analysis fol-
lowing the first stage, since no research arm passed the
lack-of-benefit assessment on progression-free survival.
For the original STAMPEDE design, the trial would
be vulnerable to greater inflation than ICON5 when
incorporating efficacy bounds at interim for the defini-
tive outcome, due to the additional two stages in the
design. A total of 19 (3%) additional control arm
events would be required to control the maximum
FWER at 2.5% when using a Haybittle–Peto efficacy
stopping rule compared to a design only assessing lack-
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of-benefit, reducing aJ from 0.0055 to 0.0045. The
O’Brien–Fleming type boundary controls the FWER at
2.5% without additional adjustment to aJ . As shown
by the simulation study, the stopping rule is too conser-
vative to impact the type I error rate, due to the use of
an intermediate outcome measure for lack-of-benefit
assessment. A custom interim rule of aE = (0.0005,
0.001, 0.002) requires the most extreme modification to
the design in order to control the FWER, with an aJ of
0.0027 requiring 12% more control arm events to be
accrued in order to have the designed power to test at
this significance level. For the original comparisons in
the STAMPEDE trial, two research arms were dropped
for insufficient benefit during the trial; as such, the
actual FWER for the remaining arms was 6.75%, not
10.32% as reported in Table 5.
Discussion
In this article, we have demonstrated how efficacy stop-
ping rules can be incorporated into MAMS designs
under the framework of Royston et al. We have also
addressed concerns about how the operating character-
istics would be affected by early assessments for effi-
cacy on the definitive outcome. There is no consensus
under which circumstances the FWER should be con-
trolled.10,23 However, we have demonstrated how to
control the FWER in practice if required, using the
four-stage original STAMPEDE trial design as an
example, by modifying the final-stage significance level,
thereby increasing the number of patients and length of
the trial. Control of the PWER could be achieved using
the same methods by specifying the trials as two-arm
designs.
In summary, our findings suggest that (binding)
lack-of-benefit stopping rules will generally decrease the
type I error rates and, marginally, the power. In con-
trast, efficacy stopping boundaries have the potential to
increase the type I error rate with no impact on power.
The simulation results indicate that the extent of this
increase primarily depends on the shape and p-value
thresholds of the stopping rule used. They also show
Table 4. Impact of the number of stages and arms on the FWER with Haybittle–Peto efficacy boundary (EB; p = 0.0005) (all
SEs\ 0.0002; lack-of-benefit boundaries as described in text; allocation ratio = 1 (for alternative allocation ratios in two-stage
designs, see Supplemental Appendix E)).
FWER Per-pair power Any-pair power All-pair power
Comparisons Stages No EB With EB Inflation Percentage No EB With EB No EB With EB No EB With EB
I = D,
binding
1 2 0.0239 0.0240 0.0001 0 0.8940 0.8940 0.8940 0.8940 0.8940 0.8940
3 0.0224 0.0225 0.0001 0 0.8771 0.8771 0.8771 0.8771 0.8771 0.8771
4 0.0213 0.0217 0.0004 2 0.8553 0.8553 0.8553 0.8553 0.8553 0.8553
2 2 0.0437 0.0437 0.0000 0 0.8942 0.8942 0.9650 0.9650 0.8234 0.8234
3 0.0410 0.0412 0.0002 0 0.8773 0.8773 0.9575 0.9575 0.7971 0.7971
4 0.0391 0.0397 0.0006 2 0.8554 0.8554 0.9475 0.9475 0.7634 0.7634
3 2 0.0605 0.0605 0.0000 0 0.8941 0.8941 0.9830 0.9830 0.7705 0.7705
3 0.0570 0.0572 0.0002 0 0.8772 0.8772 0.9788 0.9788 0.7380 0.7380
4 0.0543 0.0552 0.0009 2 0.8554 0.8554 0.9731 0.9732 0.6971 0.6971
4 2 0.0752 0.0752 0.0000 0 0.8940 0.8940 0.9900 0.9900 0.7283 0.7283
3 0.0708 0.0711 0.0003 0 0.8769 0.8769 0.9873 0.9873 0.6912 0.6912
4 0.0677 0.0688 0.0011 2 0.8552 0.8552 0.9837 0.9837 0.6458 0.6458
5 2 0.0882 0.0882 0.0000 0 0.8939 0.8939 0.9934 0.9934 0.6934 0.6934
3 0.0833 0.0837 0.0004 0 0.8769 0.8769 0.9915 0.9915 0.6537 0.6537
4 0.0798 0.0811 0.0013 2 0.8553 0.8553 0.9891 0.9891 0.6049 0.6049
I 6¼ D,
non-binding
1 2 0.0250 0.0253 0.0003 1 0.9001 0.9001 0.9001 0.9001 0.9001 0.9001
3 0.0250 0.0255 0.0005 2 0.9002 0.9002 0.9002 0.9002 0.9002 0.9002
4 0.0250 0.0260 0.0010 4 0.9000 0.9000 0.9000 0.9000 0.9000 0.9000
2 2 0.0455 0.0460 0.0005 1 0.9001 0.9001 0.9677 0.9677 0.8326 0.8326
3 0.0455 0.0463 0.0008 2 0.9002 0.9002 0.9676 0.9676 0.8327 0.8327
4 0.0455 0.0472 0.0017 4 0.9000 0.9000 0.9676 0.9676 0.8325 0.8325
3 2 0.0628 0.0635 0.0007 1 0.9001 0.9001 0.9845 0.9845 0.7818 0.7818
3 0.0627 0.0644 0.0017 3 0.9001 0.9001 0.9843 0.9843 0.7818 0.7818
4 0.0627 0.0649 0.0022 4 0.9001 0.9001 0.9845 0.9845 0.7816 0.7816
4 2 0.0780 0.0792 0.0012 2 0.9001 0.9001 0.9909 0.9909 0.7413 0.7413
3 0.0780 0.0798 0.0018 2 0.9000 0.9000 0.9909 0.9909 0.7412 0.7412
4 0.0780 0.0809 0.0029 4 0.9000 0.9000 0.9910 0.9910 0.7410 0.7410
5 2 0.0916 0.0927 0.0011 1 0.9000 0.9000 0.9941 0.9941 0.7076 0.7076
3 0.0915 0.0938 0.0023 3 0.9000 0.9000 0.9940 0.9940 0.7079 0.7079
4 0.0915 0.0950 0.0035 4 0.9000 0.9000 0.9941 0.9941 0.7076 0.7077
FWER: familywise error rate.
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that in two-stage designs the inflation remains below
2% for varying configurations of the allocation ratio,
number of research arms and timing of the analyses.
Designs with three or more stages may see greater infla-
tion of the FWER when I 6¼ D. Other parameters with
a stronger influence on the impact of efficacy looks on
the FWER are the use of an intermediate outcome mea-
sure and the final-stage significance level.
When choosing an efficacy stopping boundary, for a
three-stage design the Haybittle–Peto rule was not
observed to inflate the FWER but can be conservative.
When I 6¼ D, the Haybittle–Peto rule is recommended,
but more liberal custom rules can be used without
inflating the FWER when I = D. An O’Brien–Fleming
type rule can be implemented in a trial when I 6¼ D,
without any adjustment of the trial design to control
the maximum FWER compared to a design which con-
trols the FWER with lack-of-benefit boundaries only.
Such a rule, however, is extremely unlikely to drop arms
early due to the very conservative threshold required to
declare efficacy. For this reason, this rule is not recom-
mended providing that the investigator is willing to
modify the design as demonstrated in this article in
order to control the FWER. Figure 1 can be used to
assist in choosing an efficacy rule depending on the
design specification and how flexible the design is to
accommodate FWER control. Since non-binding lack-
of-benefit boundaries are often a regulatory require-
ment, with calculation of an upper bound for the
FWER ensuring that strong control can be achieved,
we recommend efficacy boundaries be implemented
under non-binding lack-of-benefit analysis. However,
when there are resource restrictions, for example, where
treatment selection occurs, it may be necessary for stop-
ping boundaries to be binding.
A fundamental aspect of the design is that the timing
of interim analyses is driven by the accrual of control
arm events on the intermediate outcome. At the design
stage, it should be considered whether it is too early to
assess efficacy at the interim stages based on the num-
ber of events expected on the definitive outcome. If
data from previous trials are available, a judgement
can easily be made on whether or not to implement
efficacy boundaries; otherwise, a sensitivity analysis
can be made under different assumptions for the distri-
bution of I- and D-outcomes. Royston et al.2 recom-
mend the significance level for lack-of-benefit at stage 1
be no larger than 0:5 to ensure that an adequate num-
ber of events have been accrued, with STAMPEDE
expecting 57 primary events on the control arm by the
first interim analysis under the design assumptions.
Considering the use of hypothesis testing, early
assessments of efficacy may result in some small bias in
the point estimates for the arms dropped early.
Choodari-Oskooei et al.24 demonstrated how bias in
point estimates for arms dropped for lack-of-benefit is
reduced by following up patients until the planned endT
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of the trial. We expect to observe a similar result with
efficacy boundaries, but this should be formally
explored.
The choice and definition of error rates depend on
the research question and the design of a MAMS trial.
There are at least three possible approaches on how to
proceed should a pairwise comparison for a research
arm cross an efficacy boundary: (1) stop the trial and
cease recruitment to all arms; (2) continue with the
remaining research arms to make the final decision
based on the totality of evidence and (3) add the effica-
cious regimen to the remaining arms and continue with
combination therapies in both control and remaining
research arms (e.g. the approach taken in
STAMPEDE).4 Note that this is only appropriate
where the original research arms include the control
arm. The results in this article have investigated the
first two approaches (focusing on the second), but can
also handle the third, since pairwise comparisons are
only made between the research and control arms on
patients recruited contemporaneously. Some alternative
MAMS designs adopt the first approach, where it may
be of interest to stop the entire trial as soon as an effec-
tive regimen is identified, such as in dose-ranging trials.
Examples of these are the MAMS design proposed by
Magirr et al.15 using the MAMS package in R and the
EAST6 software (http://www.cytel.com/software/east),
though neither can accommodate intermediate mea-
sures for time-to-event outcomes at the time of
submission.
We have updated the nstage program and help doc-
umentation in Stata to support the use of efficacy stop-
ping rules in MAMS trial designs and the option to
search for boundaries which preserve the FWER at the
desired level assuming non-binding lack-of-benefit
boundaries.25 The PWER, FWER and the three power
measures described are evaluated by simulation in the
program. See Supplemental Appendix D for the rele-
vant commands.
Efficacy stopping rules can easily be implemented
for alternative outcome measures in MAMS designs,
such as binary or continuous outcomes, using the same
principles applied here. The impact on the FWER can
be investigated by following the same simulation proce-
dure in nstage12 to evaluate the FWER.
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